Abstract
Since the introduction of docetaxel, research has focused on various approaches to overcome treatment limitations and improve outcome. This review discusses the pharmacological attempts at treatment optimisation, which include reducing interindividual pharmacokinetic and pharmacodynamic variability, optimising schedule, route of administration, reversing drug resistance and the development of structurally related second-generation taxanes.
MeSH terms
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / pharmacokinetics*
-
Antineoplastic Agents, Phytogenic / pharmacology*
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Docetaxel
-
Drug Administration Schedule
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Male
-
Prostatic Neoplasms / drug therapy*
-
Taxoids / administration & dosage
-
Taxoids / pharmacokinetics*
-
Taxoids / pharmacology*
-
Taxoids / therapeutic use
Substances
-
Antineoplastic Agents, Phytogenic
-
Taxoids
-
Docetaxel